Hori Masayuki, Yasumi Takahiro, Shimodera Saeko, Shibata Hirofumi, Hiejima Eitaro, Oda Hirotsugu, Izawa Kazushi, Kawai Tomoki, Ishimura Masataka, Nakano Naoko, Shirakawa Ryutaro, Nishikomori Ryuta, Takada Hidetoshi, Morita Satoshi, Horiuchi Hisanori, Ohara Osamu, Ishii Eiichi, Heike Toshio
Department of Pediatrics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Laboratory for Integrative Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
J Clin Immunol. 2017 Jan;37(1):92-99. doi: 10.1007/s10875-016-0357-3. Epub 2016 Nov 28.
Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) is a genetic disorder that results in immune dysregulation. It requires prompt and accurate diagnosis. A natural killer (NK) cell degranulation assay is often used to screen for FHL3 patients. However, we recently encountered two cases of late-onset FHL3 carrying novel UNC13D missense mutations: in these cases, the degranulation assays using freshly isolated and interleukin (IL)-2-activated NK cells yielded contradictory results. Since the defective degranulation of CD57 cytotoxic T lymphocytes (CTLs) in these cases was helpful for making the diagnosis, we assessed whether the CD57 CTL degranulation assay more effectively identified FHL3 patients than the NK cell assays.
Forty additional patients with hemophagocytic lymphohistiocytosis were prospectively screened for FHL3 by measuring the perforin expression in NK cells and the expression of Munc13-4, syntaxin-11, and Munc18-2 in platelets and by performing NK cell and CTL degranulation assays. The results were confirmed by genetic analysis.
The freshly isolated NK cell degranulation assay detected FHL3 patients with high sensitivity (100%) but low specificity (71%). The IL-2-stimulated NK cell assay had improved specificity, but 3 out of the 31 non-FHL3 patients still showed degranulation below the threshold level. The CD57 CTL degranulation assay identified FHL3 patients with high sensitivity and specificity (both 100%).
The CD57 CTL degranulation assay more effectively identified FHL3 patients than the NK cell-based assays.
3型家族性噬血细胞性淋巴组织细胞增生症(FHL3)是一种导致免疫失调的遗传性疾病。它需要迅速而准确的诊断。自然杀伤(NK)细胞脱颗粒试验常用于筛查FHL3患者。然而,我们最近遇到了两例携带新型UNC13D错义突变的迟发性FHL3病例:在这些病例中,使用新鲜分离的和白细胞介素(IL)-2激活的NK细胞进行的脱颗粒试验产生了相互矛盾的结果。由于这些病例中CD57细胞毒性T淋巴细胞(CTL)的脱颗粒缺陷有助于诊断,我们评估了CD57 CTL脱颗粒试验是否比NK细胞试验更有效地识别FHL3患者。
通过测量NK细胞中的穿孔素表达、血小板中Munc13-4、 syntaxin-11和Munc18-2的表达,并进行NK细胞和CTL脱颗粒试验,对另外40例噬血细胞性淋巴组织细胞增生症患者进行FHL3的前瞻性筛查。结果通过基因分析得到证实。
新鲜分离的NK细胞脱颗粒试验检测FHL3患者具有高敏感性(100%)但低特异性(71%)。IL-2刺激的NK细胞试验特异性有所提高,但31例非FHL3患者中有3例仍显示脱颗粒低于阈值水平。CD57 CTL脱颗粒试验以高敏感性和特异性(均为100%)识别FHL3患者。
CD57 CTL脱颗粒试验比基于NK细胞的试验更有效地识别FHL3患者。